Fiduciary Trust’s Nurix Therapeutics NRIX Stock Holding History

Fiduciary Trust’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,074	Closed	-$160K	–	866
2025 Q2	$160K	Hold	14,074	–	–	﹤0.01%	808
2025 Q1	$167K	Hold	14,074	–	–	﹤0.01%	796
2024 Q4	$265K	Hold	14,074	–	–	﹤0.01%	602
2024 Q3	$316K	Hold	14,074	–	–	﹤0.01%	555
2024 Q2	$294K	Hold	14,074	–	–	﹤0.01%	549
2024 Q1	$207K	Hold	14,074	–	–	﹤0.01%	620
2023 Q4	$145K	Hold	14,074	–	–	﹤0.01%	608
2023 Q3	$111K	Hold	14,074	–	–	﹤0.01%	598
2023 Q2	$141K	Hold	14,074	–	–	﹤0.01%	612
2023 Q1	$125K	Hold	14,074	–	–	﹤0.01%	602
2022 Q4	$155K	Hold	14,074	–	–	﹤0.01%	606
2022 Q3	$183K	Buy	14,074 +3,357	+31%	+$53.1K	﹤0.01%	590
2022 Q2	$136K	Hold	10,717	–	–	﹤0.01%	611
2022 Q1	$150K	Buy	10,717 +855	+9%	+$15.2K	﹤0.01%	649
2021 Q4	$286K	Buy	9,862 +3,182	+48%	+$96.5K	﹤0.01%	573
2021 Q3	$200K	Buy	+6,680	New	+$206K	﹤0.01%	630

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiduciary Trust's NRIX Position: Q3 2025 in Review

Fiduciary Trust sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 14,074 shares — an estimated $160K sold.

Fiduciary Trust first reported a position in NRIX in Q3 2021 and held it in 16 quarters. The position peaked at $316K in Q3 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

Fiduciary Trust reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
Fiduciary Trust sold 14,074 Nurix Therapeutics shares in Q3 2025, an estimated $160K.
Fiduciary Trust first reported a position in Nurix Therapeutics in Q3 2021 and held it in 16 quarters.
Fiduciary Trust's Nurix Therapeutics position peaked at $316K in Q3 2024.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Fiduciary Trust's 13F filing for Q3 2025, filed 14 Nov 2025.